Trials / Completed
CompletedNCT05307978
Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Subcutaneously and Intravenously Administered ALXN1910 in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single ascending doses (SADs) of ALXN1910 subcutaneous (SC) and SAD of ALXN1910 intravenous (IV).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALXN1910 | Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort. |
| DRUG | Placebo | Participants will receive Placebo IV or Placebo SC according to their assigned cohort. |
Timeline
- Start date
- 2022-04-12
- Primary completion
- 2023-02-07
- Completion
- 2023-02-07
- First posted
- 2022-04-01
- Last updated
- 2025-02-27
- Results posted
- 2025-02-27
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05307978. Inclusion in this directory is not an endorsement.